The FDA gets more involved with cannabis, moving to now regulate what they've long prohibited.

We can only hope it's an improvement over the DEA's involvement with cannabis….

* * Excerpt * *

Much of the guidance—which is “limited to the development of human drugs and does not cover other FDA-regulated products”—covers the basics of conducting federally authorized research for drug development purposes such as where researchers are allowed to obtain cannabis and the importance of demonstrating the ability to “consistently manufacture a quality product.”

“A range of stakeholders have expressed interest in development of drugs that contain cannabis and compounds found in cannabis. Recent legislative changes have also opened new opportunities for cannabis clinical research,” FDA Principal Deputy Commissioner Amy Abernethy said in a press release. “As that body of research progresses and grows, the FDA is working to support drug development in this area.”

The chief legislative change she referenced is the 2018 Farm Bill, which federally legalized hemp and its derivatives such as CBD.

For researchers, that reform means they are no longer bound to certain restrictions that exist for marijuana. For example, FDA noted in the new document that as long as a manufacturer produces hemp products that meet the federal definition of containing no more than 0.3 percent THC, scientists can use that for studies rather that rely on the nation’s only federally authorized marijuana manufacturer at the University of Mississippi.

“This change gives sponsors and investigators of clinical studies new options that do not involve the [National Institute on Drug Abuse Drug Supply Program],” FDA wrote.

* * *

Hmmm. Some baby steps? Some benefits for hemp farmers?

Your take?

#TRUCE

https://www.marijuanamoment.net/fda-releases-guidelines-on…/

FDA Releases Guidelines On Cannabis Research Following White House Review | Marijuana Moment

The Food and Drug Administration (FDA) published draft guidance on developing cannabis-based drugs on Tuesday. This comes weeks after the White House completed its review of the document, clearing its path for public release. FDA is still in the process of developing regulations that could allow for…


Source